Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has reservations on approval by the U.S. Food and Drug Administration (FDA) of another version of enoxaparin sodium.
Original Source of Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium
